[Cytomegalovirus polyradiculomyelopathy in AIDS].
To evaluate the efficacy of ganciclovir, foscarnet, or the combination of both for the treatment of cytomegalovirus polyradiculomyelopathy (CMV-PRAM), we reviewed the records of seven patients with AIDS, diagnosed with CMV-PRAM. Muscle strength was graded according to the Medical Research Council (MRC) scale. Response to treatment was also classified according to MRC scale, based on the degree of improvement in muscle strength. Six of 7 patients had a good response to treatment, reaching the MRC scale of 4, or improving at least 3 degrees in the same scale. CMV-PRAM may be treated with ganciclovir alone or in combination with foscarnet.
Department of Medicine, University of Miami School of Medicine, Florida, USA.
D T
DT
Jayaweera
L I
LI
Cassetti
L
L
Espinoza
G D
GD
Lopardo
M L
ML
Hansman-Whiteman
E G
EG
Scerpella
D017088:AIDS-Related Opportunistic Infections / Q000150:complications*; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000150:complications* / Q000188:drug therapy; D004359:Drug Therapy, Combination; D004576:Electromyography; D005260:Female; D017245:Foscarnet / Q000627:therapeutic use*; D015774:Ganciclovir / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009129:Muscle Tonus / Q000187:drug effects; D011128:Polyradiculopathy / Q000188:drug therapy* / Q000821:virology*; D013118:Spinal Cord Diseases / Q000188:drug therapy* / Q000821:virology*; D016896:Treatment Outcome; D016055:Urinary Retention / Q000188:drug therapy / Q000821:virology
D000998:Antiviral Agents; D017245:Foscarnet; D015774:Ganciclovir